Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Atsushi Satake

Showing results (71-80 of 84) with videos related to

Pageof 9
Sort By:
Journal of Blood Medicine|February 6, 2016
Relationship between HMGB1 and PAI-1 after allogeneic hematopoietic stem cell transplantationShosaku Nomura, Yoshinobu Maeda, Kazuyoshi Ishii, et al.
Hematology Reports|October 4, 2019
A variant of acute promyelocytic leukemia with t(4;17)(q12;q21) showed two different clinical symptomsTakahisa Nakanishi, Aya Nakaya, Yusuke Nishio, et al.
International Journal of Hematology|April 25, 2020
Comparison of starting doses of anagrelide as a first-line therapy in patients with cytoreductive therapy-naïve essential thrombocythemia: difference between starting at 0.5 and 1.0 mg/dayYoshinori Hashimoto, Tomoki Ito, Yasuhiro Tanaka, et al.
European Journal of Haematology|May 21, 2019
Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naïve essential thrombocythemia patients in a real-world settingTomoki Ito, Yoshinori Hashimoto, Yasuhiro Tanaka, et al.
Transplantation and Cellular Therapy|September 10, 2025
Comparison of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Primary Plasma Cell Leukemia in JapanMasaya Maegaki, Tsutomu Takahashi, Kazuhito Suzuki, et al.
Journal of Cancer Survivorship : Research and Practice|September 1, 2022
Incidence and predictors of recurrent sick leave in survivors who returned to work after allogeneic hematopoietic cell transplantationSaiko Kurosawa, Takuhiro Yamaguchi, Ayako Mori, et al.
Bone Marrow Transplantation|September 30, 2024
Impact of donor type on the outcomes of acute graft versus host disease to systemic corticosteroid therapyYoshimitsu Shimomura, Tetsuhisa Kitamura, Junichi Sugita, et al.
International Journal of Hematology|December 3, 2025
Preliminary analysis of a multicenter study of Pola-R-CHP in untreated Japanese patients with DLBCL (POLASTAR)Atsushi Satake, Yasuhiro Nagate, Kohta Miyawaki, et al.
Blood Neoplasia|June 23, 2025
Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR T-cell manufacturing failure in myelomaTomoyasu Jo, Kyoko Yoshihara, Masaki Ri, et al.
International Journal of Hematology|April 8, 2022
Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapyChikashi Yoshida, Takeshi Kondo, Tomoki Ito, et al.
Pageof 9

Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
Journal of Blood Medicine|February 6, 2016
Relationship between HMGB1 and PAI-1 after allogeneic hematopoietic stem cell transplantationShosaku Nomura, Yoshinobu Maeda, Kazuyoshi Ishii, et al.
Hematology Reports|October 4, 2019
A variant of acute promyelocytic leukemia with t(4;17)(q12;q21) showed two different clinical symptomsTakahisa Nakanishi, Aya Nakaya, Yusuke Nishio, et al.
International Journal of Hematology|April 25, 2020
Comparison of starting doses of anagrelide as a first-line therapy in patients with cytoreductive therapy-naïve essential thrombocythemia: difference between starting at 0.5 and 1.0 mg/dayYoshinori Hashimoto, Tomoki Ito, Yasuhiro Tanaka, et al.
European Journal of Haematology|May 21, 2019
Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naïve essential thrombocythemia patients in a real-world settingTomoki Ito, Yoshinori Hashimoto, Yasuhiro Tanaka, et al.
Transplantation and Cellular Therapy|September 10, 2025
Comparison of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Primary Plasma Cell Leukemia in JapanMasaya Maegaki, Tsutomu Takahashi, Kazuhito Suzuki, et al.
Journal of Cancer Survivorship : Research and Practice|September 1, 2022
Incidence and predictors of recurrent sick leave in survivors who returned to work after allogeneic hematopoietic cell transplantationSaiko Kurosawa, Takuhiro Yamaguchi, Ayako Mori, et al.
Bone Marrow Transplantation|September 30, 2024
Impact of donor type on the outcomes of acute graft versus host disease to systemic corticosteroid therapyYoshimitsu Shimomura, Tetsuhisa Kitamura, Junichi Sugita, et al.
International Journal of Hematology|December 3, 2025
Preliminary analysis of a multicenter study of Pola-R-CHP in untreated Japanese patients with DLBCL (POLASTAR)Atsushi Satake, Yasuhiro Nagate, Kohta Miyawaki, et al.
Blood Neoplasia|June 23, 2025
Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR T-cell manufacturing failure in myelomaTomoyasu Jo, Kyoko Yoshihara, Masaki Ri, et al.
International Journal of Hematology|April 8, 2022
Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapyChikashi Yoshida, Takeshi Kondo, Tomoki Ito, et al.
Pageof 9